SDS Optic #news: next milestones and inPROBE development Posted on 19 April 20229 August 2022 by Karol Maryniowski The first quarter of 2022 is already behind us. As we announced during our debut on the NewConnect market, this year is rich in many important events. We are consistently pursuing all of the Company’s objectives and are pleased to announce the achievement of the subsequent milestones of the inPROBE project – an optical fibre micoprobe for the diagnosis of HER2 positive breast cancer. What exactly happened in our Company? Achieving the milestone in the field of implementation of the pilot production of fibre optic biosensors Shortly after the debut of SDS Optic on the NewConnect market, in the ESPI system we published a current report on the completion of the first stage of milestone realisation in the field of implementation of pilot production of optoelectronic parts of optical fiber biosensors for use in inPROBE microprobes. This stage consisted of: the design process, ordering and purchasing of dedicated personalized fixed assets (production equipment and machines) worth PLN 2.4 million in total. To achieve this goal, our Company obtained funds from the issue of D-series shares and the purchase of which is indicated in the Information Document, as one of the key objectives to be achieved after the Company’s shares were listed at the NewConnect market. This constitutes a huge step towards achieving manufacturing independence in the production and preparation of the optoelectronic (photonic) parts of optical fibre biosensor (microprobe). The creation of a professional production line together with the expansion of the R&D team in the area of photonics will enable us to manufacture up to 50 thousand proprietary biosensors per year. As part of the implementation of the next stages, we plan to:– start-up and calibrate production processes,– hire new members for our R&D team,– carry out the process of validation and certification of the planned production.– elaborate certified process and production documentation. Full ESPI report (PL): https://sdsoptic.pl/wp-content/uploads/2019/01/4_2022_Raport-biezacy-ESPI_SDS-Optic_www.pdf SDS Optic Inc. as one of the 20 most innovative companies in the European Union will represent the European Pavilion at the BIO 2022 conference in San Diego, USA At the end of March, we received information that our Company was included in the 20 most technologically advanced companies in the European Union. SDS Optic Inc. and the rest of the selected companies will represent the EU in a special pavilion at the BIO 2022, the largest event of this type in the USA. The conference brings together the most important players in the biotechnology and pharmaceutical industries. From 13 to 16 June, during the conference, we plan an intensive exchange of knowledge with specialists from the BioTech and Pharma industries. This time will definitely also be filled by networking with potential future partners. We believe that our technology can significantly improve the quality of services and products in many sectors related to medicine. We want to strongly promote our inPROBE technology in terms of drug delivery monitoring in real time. The BIO 2022 event is a great opportunity to do so. The conference abounds in numerous interesting lectures and lectures that not only allow us to keep track of the latest information from the world of medicine and pharmacology, but also significantly increase our levels of creativity. The first investor chat at SDS Optic Inc. On 12 April, the first investor chat of SDS Optic Inc. took place. Our Leadership Team talked about the most important and interesting events in the life of the Company. The Company was represented by:🔹Marcin Staniszewski, Chairman of the Board, Founder and Shareholder🔹Magdalena Staniszewska, Director of Research and Development, Founder and Shareholder🔹Mateusz Sagan, Chief Operating and Business Development Officer and Shareholder. Investors could first-hand receive up-to-date information about our inPROBE fibre microprobe for less-invasive diagnosis of cancer, infectious and fungal diseases, and real-time drug delivery monitoring. The webinar present:🔹What is our development strategy🔹What is the process of cancer diagnosis today and…🔹 how the inPROBE microprobe will change that process in the future🔹What business model related to commercialization is implemented by the Company🔹What targets and plans have been adopted at SDS Optic for the next 12 months During the webinar we also:🔹Present the principles of inPROBE technology🔹Present our industrial property rights policy🔹Present the Company’s current technical infrastructure🔹Tell you how the development process of the production facilities will look like Watch the webinar recording ⤵️ 🖥️ Download the full version of the investor presentation! Signing an annex to the grant agreement under the SME Instrument Horizon2020 Since our debut on the NewConnect market, we also signed an annex to the agreement with the European Commission regarding the Company’s acquisition of a grant in the amount of €3,985,000 from the SME Instrument Horizon2020 programme. As part of this co-financing, development works are carried out, as well as clinical research and certification of the HER2+ breast cancer diagnostic microprobe device, developed under the inPROBE brand, are financed. The Commission thus confirmed the legitimacy of using the remaining part of the subsidy, originally granted in 2017. The remaining amount of €985,000 is still available to SDS Optic Inc. These resources will be used to carry out the clinical research undertaken, to finance the remuneration of the R&D team and the administration and management, as well as the work in the field of certification and communication and commercialisation of inPROBE technology. The annex was concluded in order to coordinate the schedule of the project implemented under the SME Instrument Horizon2020 programme with the work schedule of SDS Optic Inc. Full ESPI report (PL): https://sdsoptic.pl/wp-content/uploads/2019/01/4_2022_Raport-biezacy-ESPI_SDS-Optic_www.pdf
SDS Optic won the Innovation radar Prize 2020 for the best innovation created by Women. Posted on 10 February 202110 February 2021 by Karol Maryniowski SDS Optic has been granted “Women-led Innovation” award at Innovation Radar Prize 2020, a prestigious achievement announced yearly by the European Commission. The competition recognizes the best European innovation and its founder. The award has been granted for inPROBE – a photonics-based microprobe for a quick and precise breast cancer diagnostic. Breast cancer is one of the most common form of cancers. Every year more than 1,7mln women are diagnosed globally, with more than half a million deaths. A clear opportunity and chance for these patients is fast and reliable diagnosis, that today is fully based on tissue biopsy and the time consuming histopathology testing. We can change this status quo with the innovation created by Magdalena Staniszewska, PhD DSc, Co-Founder & CSO of SDS Optic Inc. The inPROBE is a disruptive diagnostics device, offering quick and precise targeted tumor markers assessment. SDS Optic has received almost €4mln European Commission funding from the SME Instrument Horizon2020 program to run clinical trials and certification of the inPROBE.
Joanna Brońska-Stąsik Posted on 7 January 20217 October 2022 by Karol Maryniowski A graduate of the Faculty of Economics at the Maria Curie-Skłodowska University in Lublin, Master of Management and Marketing, KAAD scholar, business coach with the European Institute of Business Psychology diploma. 20 years of experience in the medical devices industry. Responsible for the implementation and certification process of SDS Optic S.A. under EN ISO 13485 and for regulatory compliance in line with the MDR 2017/275. She runs the Quality Department, managing quality processes in R&D laboratories.
Magdalena Staniszewska, PhD, DSc Posted on 18 March 20195 July 2023 by Karol Maryniowski Leading biotechnology scientis with several years of experience at Harvard Medical School in Boston, MA (USA) and Polish Academy of Sciences. A scientist with broad experience in discovering molecular bases of diseases, identifying targets and developing novel therapeutic strategies for diabetic complications, cancer and eye diseases. Co-invented analytical tools and diagnostic markers of pathological neovessels, holds track record of scientific publications and public speaking.
Medical devices Posted on 8 February 201924 February 2020 by Karol Maryniowski inPROBE – disruptive platform technology with global potential to challenge the paradigm of targeted biology diagnostics and real-time targeted drugs delivery monitoring Nowadays millions of people die each year from cancer. It’s a medical professionals to save lives of patients worldwide.At the same time the future of cancer therapies is here now, several targeted or gene therapies are gaining trust, but their efficiency is strictly depends on proper and real time targeted tumor biology diagnostics, which doeas not exist yet. That’s why we’ve invented and developed inPROBE, a platform technology which links targeted therapies with targeted diagnostics.Our technology will reduce diagnosis time, increase precision and improve the effects of innovative cancer treatments. It can be used both in cancer diagnostics and therapies monitoring in real time and in a natural state, thus giving medical professionals a previously unavailable fast and efficient tool. Examination will take almost 15 minutesNumerous results are printed in real timeClear screen presents precise results Key benefits How it works inPROBEis a nano-size glass probe placed in vivo inside a very thin biopsy needle, connected to a detecting device and with innovative components on a probe tip. Thanks to it’s thickness it is safer, much less stressful and much less painful.Fast and precise cancer diagnosis combined with modern therapies can help to SAVE UP TO 30% of people diagnosed with cancer by 2030.The high sensitivity of inProbe enables it into examine even single cells. It also allows to close access to the tumor without the need to get into the tumor as today, which can lead to malignant cancer. USG examination before using inPROBEinPROBE doesn’t need to touch tumorNumerical results All the data gathered during the procedure is transferred via fiber optics into the multi- purpose detecting device. The data is then calculated using specific algorithms and presented to the oncologist as a diagnostic result – a numerical measurement with exact level of tested components (e.g. HER2 cancer biomarker). During cancer therapies inProbe will be able to measure the level of active ingredients (e.g. Trastuzumab) in cancer tumor cells, thus supporting & improving the efficiency of modern targeted cancer therapies and patients’ well-being. Testimonials SDS-MicroProbe can be a groundbreaking solution to overcome problems in current technology and enable analysis of biological processes inside the single cell in their natural state. As an expert in hematology, I am convinced that such solution would find several applications in research as well as in future cell therapies in the cancer area. Hematologist/Oncologist M.D. PhDwith several years of scientific experience at NIH Bethesda, MD, USA There is an unmet need to study biological processes within individual cells residing in their native niche. The SDS-MicroProbe addresses this shortcoming; it is a new approach in analyzing key intracellular parameters that indicate the functionality of a cell. The SDS-MicroProbe has the potential to substantially advance our ability to assess the status of living cells and thereby improve our ability to diagnose various diseases and evaluate the efficiency of interventions. Professor, PhD of Harvard Medical School Boston, MA, USA Brochure If you want to know more about our project, you can download the newest brochure here or visit our website www.inprobe.com
Optoelectronics Posted on 8 February 201924 February 2020 by Karol Maryniowski SDS OPTIC specializes in modeling and designing high-quality package components, such as ferrules, housings, and other devices with flat and conical surface areas. We employ highly accurate assembling procedures that allow us to compose hermetic patch cords, pigtails, connectors and windows. It is essential to know how the assembly phases influence the properties of optoelectronic components to avoid damage caused by thermal stresses. Specifically, it is crucial to apply proper stress distribution to all parts of the component at every manufacturing stages. As a result, we model the ideal shape and dimensions of all types of packages to achieve a mild stress allocation. Our high-precision developing processes of optoelectronics assembly ensures that our customers eliminate positioning problems during assembly steps. SDS OPTIC strongly propagates techniques, which allow to eliminate the old metallization methods, previously leading to a 25% decrease in fiber strength, the possibility of organic contamination, low manufacturing and a high rate of rejection. SDS OPTIC is capable of designing and fabricating custom-specified fiber optics Pig-Tails and Connectors. Cost-effective assembling procedures allow us gather precision products with a high level of hermeticity. The assembling method is free of time-consuming and costly pre-metallization processing. The Climatic Validation Report reveals the quality enforced during assembly. On request, test reports may accompany any shipment or consignment. A finite element thermal stress analysis is employed to achieve the proper geometry and dimension of package components. Utilizing this process, mild stress distribution is obtained among all areas of completed assemblies – as can be seen in the symmetric cross-section.
Biotech r&d Posted on 8 February 20198 April 2019 by Karol Maryniowski SDS Optic, based in Lublin, Poland, is a cutting-edge biotech company specializing in connecting vast medical knowledge with technical skills to create medical devices that can revolutionize healthcare worldwide. Our strategy is to discover, develop, produce and commercialize on global scale unique diagnostics and monitoring tools working in real-time and in natural state, which support and save lives. We concentrate on helping the healthcare with faster, less painful diagnostics and supporting targeted, effective treatment procedures. We develop and create different diagnostics & monitoring solutions, incl. the ones used in cancer diagnostics and cancer treatment. Our team consists of renown experts in biology, optoelectronics, physics, medicine, advanced technologies, chemistry and related sciences. SDS Optic is innovative integrated multidisciplinary biotechnology R&D partner for the pharmaceutical and biotechnology industries with office in Lublin, Poland and research associates both in Poland and in the United States. The company offers targeted diagnostics discovery support at every stage of the early discovery phase up to the preclinical research phase.Currently SDS Optic employs over 10 scientists, majority with PhD degree and extensive experience in several areas of life sciences, offering the following types of projects: Contract Chemistry servicesMolecular Biology services Targeted innovative multidisciplinary in vivo diagnostics & monitoring solutions developmentComparative studies of biosimilar productsIntegrated multiple key-steps pre-clinical discovery projectsEarly stage in vivo & in vitro diagnostic technologies scale-up and commercialization
